Efficacy of entecavir treatment among chronic hepatitis B nucleos(t)ide-naïve and -experienced patients
| Autor: | Fatma Bal, Sibel Özsu Caymaz, Meltem Avci, Kadir Çağatay Biçer, Vecdi Evren Genç, Alpay Ari |
|---|---|
| Přispěvatelé: | Zonguldak Bülent Ecevit Üniversitesi |
| Jazyk: | turečtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Chronic hepatitis B virus infection Hepatitis B virus predictive factors Guanine efficacy Drug resistance Gastroenterology Antiviral Agents Virological response Hepatitis B Chronic Chronic hepatitis Risk Factors Internal medicine Drug Resistance Viral Medicine Humans In patient Retrospective Studies Chronic hepatitis B virus infection entecavir efficacy predictive factors viral response lamivudine resistance business.industry Retrospective cohort study General Medicine Entecavir Hepatitis B Middle Aged Viral Load medicine.disease Virology viral response lamivudine resistance Treatment Outcome Lamivudine DNA Viral Female business Viral load medicine.drug entecavir |
| Zdroj: | Volume: 45, Issue: 1 99-104 Turkish Journal of Medical Sciences |
| ISSN: | 1300-0144 1303-6165 |
| Popis: | WOS: 000347840000016 PubMed: 25790537 Background/aim: To evaluate the efficacy of entecavir (ETV) among chronic hepatitis B (CHB) nucleos(t) ide-naive and -experienced patients in clinical practice. Materials and methods: In this retrospective study 85 CHB patients who had been receiving ETV and who attended our clinic since 2007 were included. Fifty patients were nucleos(t) ide analogue (NA)-naive. Factors including sex, positive HBeAg, baseline HBV DNA level, baseline alanine aminotransferase level, and prior lamivudine (LAM) resistance were evaluated in terms of their predictive role in treatment response, which was defined as a serum HBV DNA decrease of < 31.4 copies/mL. Results: Resistance was detected in 18 (51.4%) of 35 lamivudine-experienced patients. Virological response (VR) was achieved in 48 (96.0%) of NA-naive patients, while 16 (45.7%) of NA-experienced patients achieved VR. LAM-resistant patients had significantly lower response rates (P < 0.001). More responders with a low initial viral load achieved VR at the end of the 12-month follow-up period compared to those with a high initial viral load (91.7% vs. 70.0%, P = 0.004). Conclusion: ETV has greater efficacy in NA-naive patients and in NA-experienced patients without prior LAM resistance. The rate of VR achievement at 12 months was higher in patients who initially had a low viral load with ETV treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|